[go: up one dir, main page]

AR076810A1 - Compuestos anticancerigenos de amino pirimidina - Google Patents

Compuestos anticancerigenos de amino pirimidina

Info

Publication number
AR076810A1
AR076810A1 ARP100101897A ARP100101897A AR076810A1 AR 076810 A1 AR076810 A1 AR 076810A1 AR P100101897 A ARP100101897 A AR P100101897A AR P100101897 A ARP100101897 A AR P100101897A AR 076810 A1 AR076810 A1 AR 076810A1
Authority
AR
Argentina
Prior art keywords
halogen
independently
optionally substituted
compounds
alkoxy
Prior art date
Application number
ARP100101897A
Other languages
English (en)
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of AR076810A1 publication Critical patent/AR076810A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6544—Six-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Sus formulaciones, y su uso en el tratamiento de enfermedades con dichos compuestos, que abarcan tipos de cáncer mediados, al menos en parte, por FAK. Reivindicacion 1: Un compuesto de la Formula 1: donde: R1 es halogeno, -CF3 , o -CCH; por lo menos uno de Q2-Q4 es -C-X1-R2; Q1 y los restantes Q2-Q4 son, de manera independiente, CH, CF, N, o N-oxido; X1 y X2 son, de manera independiente, -(CR7R8)0-2-; cada R7 y R8 es, de modo independiente, halogeno, alifático C0-3, o -OalifáticoC0-3, cualquiera de los cuales está opcionalmente sustituido con halogeno, excepto que en el caso de X2, R7 y R8 no son halogeno u -OalifáticoC0-3; R6 es halogeno, -OalifáticoC0-3 o -alifáticoC0-3, cualquiera de los cuales está opcionalmente sustituido con uno o más halogeno o -OCF3 R2 es P(O)R9R10; R9 y R10 son, de modo independiente, alcoxi C0-3, cualquiera de los cuales pueden tomarse juntos en cualquiera de sus átomos a fin de formar un anillo, donde cualquiera de los anteriores puede estar adicionalmente sustituido con uno o más halogeno, alcoxi C0-3 o cíclico 3-6; R es un compuesto de la formula 2; uno de Q6, Q7, o A es -CR4; Q5 y los restantes Q6-Q7 y A son, de manera independiente, CH, CF, N, o N-oxido; R3 es alifático C0-6, -S(O)2R11, -S(O)2NR11R12, -C(O)NR11R12, -C(O)OR11 -NR11S(O)2R12, o -NR11R12; R11 y R12 son, de manera independiente, alquilo C0-6, y pueden tomarse juntos en cualquiera de sus átomos a fin de formar un anillo que contiene 1-3 heteroátomos; o, alternativamente, R3 y A definen cualquier cíclico 5-6 opcionalmente sustituido que contiene uno o más heteroátomos; R4 es cíclico4-6, alcoxi C0-6 o alifático C0-6, cada uno, opcionalmente sustituido; o halogeno; o una de sus sales farmacéuticamente aceptables.
ARP100101897A 2009-06-01 2010-05-31 Compuestos anticancerigenos de amino pirimidina AR076810A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18289809P 2009-06-01 2009-06-01
US29834910P 2010-01-26 2010-01-26

Publications (1)

Publication Number Publication Date
AR076810A1 true AR076810A1 (es) 2011-07-06

Family

ID=43298430

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101897A AR076810A1 (es) 2009-06-01 2010-05-31 Compuestos anticancerigenos de amino pirimidina

Country Status (18)

Country Link
US (2) US8399433B2 (es)
EP (1) EP2438056B1 (es)
JP (1) JP5718324B2 (es)
KR (1) KR20120034676A (es)
CN (1) CN102448955B (es)
AR (1) AR076810A1 (es)
AU (1) AU2010256865A1 (es)
BR (1) BRPI1013760A2 (es)
CA (1) CA2757083A1 (es)
EA (1) EA021801B1 (es)
ES (1) ES2655882T3 (es)
IL (1) IL215490A0 (es)
MX (1) MX2011012797A (es)
PL (1) PL2438056T3 (es)
PT (1) PT2438056T (es)
TW (1) TW201100441A (es)
WO (1) WO2010141406A2 (es)
ZA (1) ZA201108721B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2010064628A1 (ja) * 2008-12-05 2012-05-10 オリンパス株式会社 核酸含有試料の調製方法、試料調製用溶液、及び核酸の解析方法
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
MX2012014158A (es) 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
PT3124483T (pt) 2010-11-10 2019-10-02 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
AU2012216894B2 (en) 2011-02-17 2016-07-14 Cancer Therapeutics Crc Pty Limited Selective FAK inhibitors
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
ES2698847T3 (es) * 2011-07-07 2019-02-06 Merck Patent Gmbh Azaheterociclos sustituidos para el tratamiento del cáncer
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
US9822135B2 (en) 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
EP2738171A1 (en) 2012-11-30 2014-06-04 Syngenta Participations AG. Pesticidally active tricyclic pyridyl derivatives
CA2900012A1 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
MX2016007898A (es) 2013-12-20 2016-10-07 Signal Pharm Llc Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos.
AR099428A1 (es) * 2014-02-14 2016-07-20 Aicuris Gmbh & Co Kg Combinaciones de principios activos farmacéuticos con compuestos basados en tri(hetero)aril pirazoles
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
ES2796701T3 (es) * 2015-02-04 2020-11-30 Univ Bologna Alma Mater Studiorum Aditivo para acelerar la hibridación
KR101691536B1 (ko) * 2015-11-06 2017-01-02 한국원자력의학원 신규 fak 저해제를 유효성분으로 포함하는 방사선 민감성 증진용 조성물
US10294256B2 (en) 2016-12-13 2019-05-21 Bristol-Myers Squibb Company Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
SG11202010925UA (en) 2018-05-29 2020-12-30 Omeros Corp Masp-2 inhibitors and methods of use
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
WO2020006724A1 (zh) * 2018-07-05 2020-01-09 清华大学 一种靶向降解fak蛋白的化合物及其应用
SG11202112336PA (en) 2019-05-10 2021-12-30 Deciphera Pharmaceuticals Llc Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PT3966206T (pt) 2019-05-10 2023-11-10 Deciphera Pharmaceuticals Llc Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de utilização dos mesmos
AU2020297422B2 (en) 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
AU2020347274A1 (en) 2019-09-13 2022-03-31 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
AU2020396565C1 (en) 2019-12-04 2025-05-15 Omeros Corporation MASP-2 inhibitors and methods of use
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
KR20220110530A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2022253081A1 (zh) * 2021-06-03 2022-12-08 希格生科（深圳）有限公司 氧化膦衍生物及其制备方法和应用
CN113546085B (zh) * 2021-07-19 2023-04-25 合肥工业大学 一种手性双膦酰二胺化合物的用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US80182A (en) * 1868-07-21 Improved fly-net for hoeses
JP2002523497A (ja) * 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
YU66502A (sh) 2000-03-06 2005-09-19 Warner-Lambert Company 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
MEP13408A (en) 2001-05-29 2010-06-10 Bayer Schering Pharma Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
AU2002315388A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ES2338545T3 (es) * 2002-12-20 2010-05-10 Pfizer Products Inc. Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE602004021472D1 (en) * 2003-02-20 2009-07-23 Smithkline Beecham Corp Pyrimiidinverbindungen
US7230098B2 (en) * 2003-02-26 2007-06-12 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
BRPI0413616B8 (pt) 2003-08-15 2021-05-25 Irm Llc 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｒｔｋ阻害剤としての６−置換アニリノプリン類
EP1663991B1 (en) 2003-09-05 2007-01-10 Pfizer Products Inc. Selective synthesis of cf3-substituted pyrimidines
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) 2004-08-27 2004-09-29 Novartis Ag Organic compounds
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
DE102005008310A1 (de) 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1940843A4 (en) 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
AU2006327871A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MX2009004426A (es) 2006-10-23 2009-08-12 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
GEP20125691B (en) * 2006-12-08 2012-11-26 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008079073A1 (en) * 2006-12-22 2008-07-03 Astrazeneca Ab Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders
EA200900983A1 (ru) 2007-01-26 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов киназы
US20110281821A9 (en) 2007-01-30 2011-11-17 Biogen Idec Ma Inc. Modulators of Mitotic Kinases
CA2681516A1 (en) 2007-03-22 2008-09-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of janus kinases
NZ580372A (en) * 2007-04-18 2012-01-12 Pfizer Prod Inc Pyrimidine and triazine derivatives including a sulfonamide group for the treatment of abnormal cell growth such as cancer
US7981903B2 (en) 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
CA2707653A1 (en) 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
JP2011512413A (ja) 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
PT2300013T (pt) * 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US8815872B2 (en) 2008-09-08 2014-08-26 Merck Patent Gmbh Macrocyclics pyrimidines as aurora kinase inhibitors
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
PT2646448T (pt) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Inibidores macrocíclicos de cinases
AU2012250517B2 (en) * 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN103596956A (zh) 2011-06-07 2014-02-19 辉瑞大药厂 吡唑并[3,4-d]嘧啶化合物及其作为PDE2抑制剂和/或CYP3A4抑制剂的用途

Also Published As

Publication number Publication date
US20130231306A1 (en) 2013-09-05
MX2011012797A (es) 2012-01-27
EP2438056A4 (en) 2012-12-19
KR20120034676A (ko) 2012-04-12
WO2010141406A3 (en) 2011-04-21
AU2010256865A1 (en) 2011-11-03
US9096624B2 (en) 2015-08-04
WO2010141406A2 (en) 2010-12-09
BRPI1013760A2 (pt) 2016-04-05
IL215490A0 (en) 2011-12-29
PL2438056T3 (pl) 2018-03-30
TW201100441A (en) 2011-01-01
PT2438056T (pt) 2018-01-19
ZA201108721B (en) 2012-10-31
CN102448955B (zh) 2014-06-18
JP2012528864A (ja) 2012-11-15
US8399433B2 (en) 2013-03-19
US20110136764A1 (en) 2011-06-09
JP5718324B2 (ja) 2015-05-13
EP2438056A2 (en) 2012-04-11
EA021801B1 (ru) 2015-09-30
ES2655882T3 (es) 2018-02-22
CN102448955A (zh) 2012-05-09
CA2757083A1 (en) 2010-12-09
EA201171489A1 (ru) 2012-05-30
EP2438056B1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
AR076810A1 (es) Compuestos anticancerigenos de amino pirimidina
CO2018001425A2 (es) Compuestos di-nucleótidos cíclicos como agonistas de sting
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR045387A1 (es) Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo
ECSP19026680A (es) COMPUESTOS DE BENZO[b]TIOFENO COMO AGONISTAS DE STING
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
AR078793A1 (es) Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
PE20090042A1 (es) Analogos de ciclopamina
CY1113002T1 (el) Παραγωγα μακροκυκλικης κιναζολινης ως αντιπολλαπλασιαστικοι παραγοντες
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
AR061181A1 (es) Compuestos de aziridinil-epotilona
AR049443A1 (es) Derivados de pirrolpiridinas
AR065280A1 (es) Agentes antiparasitarios
PE20130157A1 (es) Inhibidores de la polimerasa virica
AR060914A1 (es) Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico.
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
MX2016017405A (es) Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen.
AR122726A1 (es) Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure